Centessa Pharmaceuticals plc (CNTA)
$40.50+0.00%Close
BUYBULL · day 57
Key stats
- Market cap
- $6.3B
- Beta
- 1.12
- P/E (TTM)
- -22.75
- 1W
- +0.80%
- 1M
- +1.73%
- vs SPY 1W
- +0.94%
- vs SPY 1M
- -0.77%
Industry peers
FMP comparable companies · ranked by market cap
- EWTXSELLEdgewise Therapeutics, Inc.$4.2BCRISISQ 15$39.23-5.64%
- NAMSSELLNewAmsterdam Pharma Company N.V.$2.5BCRISISQ 24$21.26-4.99%
- CGEMSELLCullinan Therapeutics, Inc.$950MCRISISQ 1$15.46-5.69%
- GLUESELLMonte Rosa Therapeutics, Inc.$872MCRISISQ 7$10.32-5.99%
- DSGNSELLDesign Therapeutics, Inc.$718MCRISISQ -14$11.49-10.36%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on CNTA?
- LOPJLB’s latest quantitative signal on Centessa Pharmaceuticals plc (CNTA) is BUY in a BULL regime. Signals are updated daily.
- What market regime is CNTA in?
- Centessa Pharmaceuticals plc (CNTA) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Centessa Pharmaceuticals plc (CNTA) do?
- Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant…